Amphion Innovations PLC Sale of Partner Company Shares (8778L)
10 Setembro 2019 - 12:56PM
UK Regulatory
TIDMAMP
RNS Number : 8778L
Amphion Innovations PLC
10 September 2019
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Sale of Partner Company Shares
London and New York, 10 September 2019 - Amphion Innovations plc
(AIM: AMP), the developer of medical, life science, and technology
businesses, announces that 1,150,000 shares in Partner Company,
Polarean Imaging plc ("Polarean") have been sold ("Sale") for
partial repayment of the loan facility (the "Facility") originally
announced on 5 June 2014 and most recently amended as announced on
1 April 2019 ("Amendment Agreement"). Following this Sale, Amphion
holds 17,122,523 ordinary shares of Polarean, representing 14.96%
of the issued share capital.
The Sale generated total proceeds of approximately US $313,127,
which will be applied to reduce the loan balance under the
Facility. The loan amount under the Facility continues to be
secured by the pledge of 17,122,523 ordinary shares of
Polarean.
Following the Sale, the loan balance outstanding is
approximately US $2.3 million (excluding the lender's share of the
pledged share price appreciation which is currently approximately
US $172,500). The current value of the remaining shares pledged as
security for the outstanding loan is approximately US $4.4 million.
The outstanding loan is repayable on 30 September 2019. Amphion has
transferred the legal title to, but retains the beneficial interest
in, the total pledged shares in Polarean.
Amphion is working hard to try and replace or amend the Facility
to extend the repayment date past 30 September 2019 to ensure the
Company does not have to sell more shares than entirely necessary.
We are excited by and steadfastly believe in the future prospects
of Polarean and its important technology.
Amphion remains highly cash constrained and continues to
consider both its short term and medium term financing options and
work with its debt providers. Further to the Company's announcement
on 27 June 2019, the Company's shares remaining suspended from
trading on AIM.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Amphion Innovations Tel: +1 (212) 210 6224
Charlie Morgan
Panmure Gordon Limited (Nominated Adviser Tel: +44 (0)20
and Corporate Broker) 7886 2500
Emma Earl/ Freddy Crossley (Corporate
Finance)
Charles Leigh-Pemberton (Corporate
Broking)
SP Angel Corporate Finance LLP (Joint Corporate Tel: +44 (0) 20
Broker) 3470 0470
David Hignell (Corporate Finance)
Vadim Alexandre (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or amphion@walbrookpr.com
Anna Dunphy / Paul
McManus
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and
technology businesses.
We use our extensive experience in company building to invest
and build shareholder value in high growth companies in the US and
UK. Amphion has significant shareholding in 7 Partner Companies
developing proven technologies targeting substantial commercial
marketplaces. The Amphion model has been refined to optimise the
commercialisation of patents and other intellectual property within
the Partner Companies. The Partner Companies collectively own or
control over 200 separately identified pieces of intellectual
property, a number which grows rapidly each year.
On the web: www.amphionplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DISEASNEFSLNEFF
(END) Dow Jones Newswires
September 10, 2019 11:56 ET (15:56 GMT)
Amphion Innovations (LSE:AMP)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Amphion Innovations (LSE:AMP)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025